Free Trial
ASX:EX1

Exopharm (EX1) Stock Price, News & Analysis

About Exopharm Stock (ASX:EX1)

Advanced Chart

Key Stats

Today's Range
N/A
50-Day Range
N/A
52-Week Range
N/A
Volume
N/A
Average Volume
N/A
Market Capitalization
A$1.93 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Receive EX1 Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Exopharm and its competitors with MarketBeat's FREE daily newsletter.

EX1 Stock News Headlines

Tryptamine Therapeutics Ltd (TYP)
Presidential Bombshell: $150T Resource to Be Released as soon as this Summer?
Something extraordinary is happening in Washington. For the first time in over a century, a sitting President could release a national treasure that's been tied up in red tape, for generations. I'm talking about a $150 trillion American asset that's scattered across all 50 states. While the mainstream media focuses on political theater, this story is quietly developing behind closed doors.
EX1 - Weather warnings issued
Exopharm Limited (EX1.XA)
See More Headlines

Industry, Sector and Symbol

Stock Exchange
ASX
Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
Current Symbol
ASX:EX1
CIK
N/A
Fax
N/A
Employees
50
Year Founded
N/A

Profitability

EPS (Trailing Twelve Months)
A($0.04)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-A$4.32 million
Net Margins
-1,756.70%
Pretax Margin
N/A
Return on Equity
-160.86%
Return on Assets
-51.37%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
7.82
Quick Ratio
2.03

Sales & Book Value

Annual Sales
A$1.18 million
Price / Sales
0.00
Cash Flow
N/A
Price / Cash Flow
3.39
Book Value
A$0.02 per share
Price / Book
N/A

Miscellaneous

Outstanding Shares
439,420,000
Free Float
N/A
Market Cap
A$1.93 million
Optionable
Not Optionable
Beta
1.26
Beginner's Guide To Retirement Stocks Cover

Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

This page (ASX:EX1) was last updated on 7/12/2025 by MarketBeat.com Staff
From Our Partners